Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trialCentral MessagePerspective

Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trialCentral MessagePerspective

Objectives: Postoperative atrial fibrillation is the most common clinical complication after coronary artery bypass graft surgery. It is associated with a high risk of both stroke and death and increases the length of hospital stay and costs. This study aimed to evaluate anticoagulants in postoperat...

Full description

Bibliographic Details
Main Authors: Marcel de Paula Pereira, MD, Eduardo Gomes Lima, MD, PhD, Fabio Grunspun Pitta, MD, Luís Henrique Wolff Gowdak, MD, PhD, Bruno Mahler Mioto, MD, PhD, Leticia Neves Solon Carvalho, MD, Francisco Carlos da Costa Darrieux, MD, PhD, Omar Asdrubal Vilca Mejia, MD, PhD, Fabio Biscegli Jatene, MD, PhD, Carlos Vicente Serrano, Jr, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:JTCVS Open
Subjects:
postoperative atrial fibrillation
anticoagulation
direct oral anticoagulant
coronary artery bypass surgery
cost-effective
costs
Online Access:http://www.sciencedirect.com/science/article/pii/S2666273623001201

Internet

http://www.sciencedirect.com/science/article/pii/S2666273623001201

Similar Items